Human immunodeficiency virus type 1 trans-activator of transcription (HIV-1 Tat)

The Human immunodeficiency virus type 1 trans-activator of transcription (HIV-1 Tat) is a critical regulatory protein required for viral gene expression and replication (UniProt: P04608). In the context of therapeutic vaccination, the target is specifically the Tat protein as it is recognized and neutralized by induced anti-Tat antibodies. These antibodies are designed to bind to highly conserved epitopes of the Tat protein, particularly the N-terminal and basic domains, to block its extracellular activities (PubMed: 20421993). Extracellular Tat is known to facilitate viral spread, induce apoptosis in uninfected T-cells, and contribute to HIV-associated neurocognitive disorders (PubMed: 23565094). By inducing a robust antibody response, therapeutic vaccines like Tat Oyi aim to neutralize these effects and reduce the viral reservoir (PubMed: 26927164). This approach targets the protein's role as a virokine that modulates the host immune environment to favor viral persistence. Consequently, monitoring anti-Tat antibody titers serves as a key biomarker for the efficacy of such interventions (PubMed: 25312385).

Other names

Tat proteinp14Trans-activator of transcriptionHIV-1 Tat

Neutralization of extracellular Tat protein to prevent viral transactivation and immune dysfunction.